Company news
Knight Therapeutics, Inc. (TSX:GUD) news
Knight Therapeutics, Inc. news releases on 6ix. Latest, Jul 31, 2025: Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI®…
Press releases — page 2
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil
July 31, 2025
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil
July 31, 2025
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
July 18, 2025
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
July 18, 2025
Knight Therapeutics Announces Closing of Previously Announced Acquisition of Paladin
June 17, 2025
Knight Closes US$50 Million Revolving Credit Facility with NBC
June 17, 2025
Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio
June 5, 2025
Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo's Canadian Portfolio
June 5, 2025
Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City
May 13, 2025
Knight Therapeutics Reports First Quarter 2025 Results
May 8, 2025
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
May 7, 2025
Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico
May 7, 2025
Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico
May 7, 2025
Notice of Knight Therapeutics' First Quarter 2025 Results Conference Call
May 1, 2025
Knight to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
April 29, 2025
Knight Therapeutics Inc. ranks on The Globe and Mail's sixth-annual Women Lead Here benchmark of executive gender diversity
March 28, 2025
Knight Therapeutics Inc. ranks on The Globe and Mail’s sixth-annual Women Lead Here benchmark of executive gender diversity
March 28, 2025
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
March 26, 2025
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
March 26, 2025
Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results
March 20, 2025
Notice of Knight Therapeutics' Fourth Quarter and Year End 2024 Results Conference Call
March 13, 2025
Knight Therapeutics to Acquire Paladin
March 11, 2025
IIROC Trade Resumption - GUD
May 13, 2021
IIROC Trading Halt - GUD
May 13, 2021
Maverix Private Equity Announces Team Additions
May 3, 2021
S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index
December 11, 2020
Medison Expresses Concerns over Knight Therapeutics' Second Quarter Results and Demands Answers to Critical Questions from Jonathan Goodman
August 9, 2019
Medison Urges Fellow Shareholders to Bring Positive Change to Knight Therapeutics by Voting for All Six of Medison's Highly Qualified Nominees at Upcoming Annual Meeting
April 29, 2019
Leading Independent Proxy Advisory Firm ISS Recommends Change at Knight Therapeutics
April 25, 2019
Medison Issues Presentation to Knight Shareholders
April 18, 2019
Leading Canadian Corporate Governance Expert Confirms Acute Board Conflicts and Governance Deficiencies at Knight Therapeutics
April 17, 2019
Medison Issues Letter to Shareholders of Knight Therapeutics, Outlining Qualified, Independent Director Nominees and Common-Sense Plan to Build Value
April 16, 2019
Medison Disappointed that Knight Therapeutics has Resorted to Blatant Misrepresentations to Avoid Scrutiny
April 10, 2019
Medison Files Proxy Circular, Offers Knight Therapeutics Shareholders Truly Independent, Unconflicted Directors and Comprehensive Business Plan to Fix a Failing Knight
April 8, 2019
Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders
April 1, 2019
Knight Therapeutics and Jaguar Health Announce Strategic Partnership
September 24, 2018
Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid Drug Dependence
June 13, 2017
Research Reports Initiated on Healthcare Stocks Valeant Pharmaceuticals International, Merus Labs International, and Knight Therapeutics
March 9, 2017
Profounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States
March 22, 2016
IIROC Trade Resumption - Knight Therapeutics Inc.
December 4, 2014
IIROC Trade Halt - Knight Therapeutics Inc.
December 3, 2014
IIROC Trading Resumption - GUD
February 28, 2014